Home » Stocks » MESO

Mesoblast Limited (MESO)

Stock Price: $9.60 USD 0.07 (0.73%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
After-hours: $9.15 -0.45 (-4.69%) Feb 25, 5:40 PM
Market Cap 1.18B
Revenue (ttm) 16.41M
Net Income (ttm) -97.00M
Shares Out 583.95M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE 454.55
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $9.60
Previous Close $9.53
Change ($) 0.07
Change (%) 0.73%
Day's Open 9.70
Day's Range 9.50 - 9.80
Day's Volume 284,104
52-Week Range 3.12 - 21.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics ...

The Motley Fool - 2 weeks ago

One of its pipeline candidates achieved great results in a late-stage clinical study.

Benzinga - 2 weeks ago

Positive results from Mesoblast Limited's (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company's shares higher in the premarket after an announ...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to pro...

GlobeNewsWire - 4 weeks ago

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its ...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executi...

The Motley Fool - 1 month ago

The company announced positive results from a clinical trial.

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional resul...

The Motley Fool - 2 months ago

Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to pro...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patien...

The Motley Fool - 2 months ago

The company reported disappointing results from a late-stage clinical study.

Benzinga - 2 months ago

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the ...

Other stocks mentioned: AVXL, BNTX, LLY, VTVT
GlobeNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to pro...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 7, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MES...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - December 7, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesob...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited (...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between Ap...

GlobeNewsWire - 2 months ago

Biomarker Study Results Presented at the 62nd American Society of Hematology Annual Meeting Biomarker Study Results Presented at the 62nd American Society of Hematology Annual Meeting

PRNewsWire - 2 months ago

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 202...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)-- #Classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the ...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast” or "the Company") (NASDAQ: ME...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - December 4, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesobl...

GlobeNewsWire - 2 months ago

Investors with losses are encouraged to contact the firm before December 7, 2020; click here to submit trade information

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 a...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - December 3, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesob...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - December 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesobl...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United ...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 1, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between Ap...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - December 1, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesob...

PRNewsWire - 2 months ago

NEW YORK, Nov. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and O...

Insider Monkey - 2 months ago

We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions ...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited  (“Mesoblast” or the “Company”) (NASDAQ: MESO) and cert...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - November 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MES...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - November 20, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between A...

The Motley Fool - 3 months ago

Investors are excited about the biotech's new collaboration with Novartis.

Zacks Investment Research - 3 months ago

Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.

Other stocks mentioned: NVS
GlobeNewsWire - 3 months ago

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational and f...

GlobeNewsWire - 3 months ago

Initial Focus on Acute Respiratory Distress Syndrome, including COVID-19 Initial Focus on Acute Respiratory Distress Syndrome, including COVID-19

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to pro...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - November 17, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between A...

PRNewsWire - 3 months ago

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and O...

About MESO

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for adv... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Silviu Itescu
Employees
102
Stock Exchange
NASDAQ
Ticker Symbol
MESO
Full Company Profile

Financial Performance

In 2020, Mesoblast's revenue was $32.16 million, an increase of 92.30% compared to the previous year's $16.72 million. Losses were -$77.94 million, -13.21% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Mesoblast is 14.96, which is an increase of 55.83% from the latest price.

Price Target
$14.96
(55.83% upside)